Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.42 |
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460085 | 0.89 | KIF11 (0.42) | NR3C1PGRS1PR1TRPA1AR | |
| SCHEMBL1459739 | 0.81 | ORAI1 (0.43) | — | |
| SCHEMBL12826211 | 0.80 | TRPA1 (0.38) | NR3C1PGRS1PR1TRPA1 | |
| SCHEMBL1459541 | 0.80 | TRPA1 (0.44) | S1PR1TRPA1KIF11 | |
| SCHEMBL12825438 | 0.79 | TRPA1 (0.39) | S1PR1TRPA1 | |
| SCHEMBL1459665 | 0.79 | KDM4E (0.46) | S1PR1TRPA1 | |
| SCHEMBL1460941 | 0.73 | PTGES (0.42) | S1PR1TRPA1 | |
| SCHEMBL1460846 | 0.73 | HPN (0.39) | TRPA1KIF11 | |
| SCHEMBL28022855 | 0.72 | RORC (0.46) | NR3C1PGRKIF11 | |
| SCHEMBL15021948 | 0.71 | TRPV3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | claimed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | NR3C1 1112/4885PGR 2155/4885S1PR1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.